Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

They were randomized to either titration of that dose up to 4.5 mg or switched to tirzepatide titrated up to 15 mg (or maximum tolerated doses of both). Most in both groups were also taking oral ...

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

The researchers found that at week 40, the change from baseline in HbA1c was −1.44 and −0.67% with tirzepatide and dulaglutide escalation to 4.5mg or maximum tolerated dose, respectively.

It is not sold by Eli Lilly in any oral format. Lexaria's Study was designed to discover whether the active drug within Zepbound® - tirzepatide - could be administered using Lexaria's patented ...

The trial examined the effect of Eli Lilly’s glucagon-like peptide-1 receptor agonist (GLP-1RA) tirzepatide ... Patients were on a starting dose of 2.5mg/week, which was uptitrated by 2.5mg ...